Business
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, April 17, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.","length":284,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":224,"url":"https://media.zenfs.com/en/prnewswire.com/fe1cdf34ab33551d46f10ff7ef733f1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Dn_Wwg7.U41G3SV0IH_xMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NQ--/https://media.zenfs.com/en/prnewswire.com/fe1cdf34ab33551d46f10ff7ef733f1c","width":400,"height":224}},"href":"https://mma.prnewswire.com/media/2959033/badge.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Marking the sixth consecutive year that WuXi Biologics has received this honor, the recognition highlights the company's unwavering commitment to advancing sustainability throughout its global business operations and value chain, and demonstrates the success of its long-term sustainability strategy and its vision as a Green CRDMO leader.","length":343,"tagName":"p"},{"type":"text","content":"Morningstar Sustainalytics is a leading independent ESG research, ratings, and analytics provider supporting global investors in the development and implementation of responsible investment strategies. Its 2026 ESG Risk Ratings assessed around 15,000 companies worldwide across 42 industries, with ESG Leader distinctions awarded to companies demonstrating robust ESG risk management and performance relative to their peers across industries and regions. In July 2025, WuXi Biologics was also placed in Sustainalytics' highest ESG rating tier of negligible risk, achieving a top 1% global ranking score.","length":607,"tagName":"p"},{"type":"text","content":"Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented: "We are honored to once again be recognized by Morningstar Sustainalytics. As a proactive leader in sustainability, we are committed to collaborating with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and advancing respo...